Education
About Us
Working with TipRanks
Follow Us
Nurix Therapeutics, Inc. (NRIX)
NASDAQ:NRIX
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 83.98M | $ 54.55M | $ 76.99M | $ 38.63M | $ 29.75M |
| Gross Profit | $ 65.12M | $ -167.08M | $ -112.16M | $ -145.87M | $ -86.68M |
| Operating Income | $ -285.67M | $ -213.03M | $ -155.06M | $ -183.87M | $ -117.89M |
| EBITDA | $ -244.84M | $ -205.01M | $ -148.93M | $ -179.72M | $ -115.90M |
| Net Income | $ -264.46M | $ -193.57M | $ -143.95M | $ -180.36M | $ -117.19M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 592.94M | $ 609.58M | $ 287.91M | $ 309.14M | $ 295.72M |
| Total Assets | $ 688.13M | $ 669.34M | $ 355.60M | $ 416.76M | $ 476.77M |
| Total Debt | $ 55.73M | $ 28.30M | $ 30.61M | $ 11.96M | $ 13.04M |
| Net Debt | $ -191.23M | $ -81.69M | $ -24.01M | $ -52.51M | $ -67.47M |
| Total Liabilities | $ 149.39M | $ 142.35M | $ 155.10M | $ 113.06M | $ 134.47M |
| Stockholders' Equity | $ 538.75M | $ 526.99M | $ 200.49M | $ 303.70M | $ 342.30M |
| Cash Flow | |||||
| Free Cash Flow | $ -263.47M | $ -181.86M | $ -89.77M | $ -172.05M | $ -90.03M |
| Operating Cash Flow | $ -249.47M | $ -172.58M | $ -81.36M | $ -159.81M | $ -84.36M |
| Investing Cash Flow | $ 147.85M | $ -257.71M | $ 68.30M | $ 27.20M | $ -108.25M |
| Financing Cash Flow | $ 238.64M | $ 485.67M | $ 3.22M | $ 117.19M | $ 153.88M |